Skip to main content
GSK logo

GSK plc (GSK) Stock: Price, Forecast & Analyst Target

GSK plc (GSK) — MoonshotScore 77/100 (Strong band), calculated Nov 18, 2026. Price $48.58 (-1.34%), as of the Nov 18, 2026 trading session; market cap $97.4B. Expected results Feb 3, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$48.58 −$0.66 (-1.34%) Market Cap $97.4B

GSK plc · GSK · NYSE · Healthcare · Drug Manufacturers - General

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions.

Price as of Nov 18, 2026

Key Statistics

77 of 100

MoonshotScore v2 · GSK (GSK)

Strong
Business Quality Elite (89)
Financial Safety Okay (54)
Valuation Fair (70)
Growth Durability Flat (42)
Momentum Rising (74)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Rising.

  • EPS beat 8 of the last 8 reports
  • Altman Z 1.80 · Piotroski F 8
  • ROE 28.3% · ROA 9.6% · current ratio 0.86

Helping: business quality, an attractive price, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GSK (52 recorded, newest six shown)
RecordedScoreBand
83Exceptional
84Exceptional
84Exceptional
84Exceptional
77Strong
77Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$48.58
Change on the day-1.34%
52-week range$45.81–$61.70
Market capitalisation$97.4B—
Price / earnings (trailing)17.31
Shares traded on the day2.02M
Beta (volatility vs the S&P 500)0.28

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $43, high $60, latest $49. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $60 $43 high $60 Feb 4, 2026 · Earnings results · reported above the recorded estimate · close $601Apr 29, 2026 · Earnings results · reported above the recorded estimate · close $522Jul 28, 2026 · Earnings results · reported above the recorded estimate · close $523Oct 28, 2026 · Earnings results · reported above the recorded estimate · close $504 Oct 17, 2025 Nov 18, 2026 · $49 $44Oct 17, 2025$47Oct 31, 2025$47Nov 14, 2025$48Nov 28, 2025$49Dec 12, 2025$49Dec 26, 2025$50Jan 9, 2026$49Jan 23, 2026$60Feb 6, 2026$60Feb 20, 2026$55Mar 6, 2026$52Mar 20, 2026$57Apr 2, 2026$58Apr 17, 2026$52May 1, 2026$50May 15, 2026$51May 29, 2026$53Jun 12, 2026$53Jun 26, 2026$53Jul 10, 2026$51Jul 24, 2026$53Aug 7, 2026$52Aug 21, 2026$50Sep 4, 2026$50Sep 18, 2026$47Oct 2, 2026$50Oct 16, 2026$50Oct 30, 2026$50Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for GSK (GSK): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Moderate
Revenue Growth Neutral
Debt/Equity Negative
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is GSK (GSK), and what does it report?

Short answer

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. GSK plc (GSK) is listed on NYSE. Healthcare / Drug Manufacturers General SEC filing business address: 79 NEW Oxford Street, London, WC1A 1DG. It employs 66,841 people and is led by Luke Victor Miels. The market values it at $97.4B.

2 · Latest results

What do the latest results show for GSK (GSK)?

Short answer · as of

Against analyst estimates the company has EPS beat 8 of the last 8 reports.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$11.82B Oct 28, 2026
Latest report · revenue estimate
$11.78B Oct 28, 2026
Latest report · revenue vs estimate
Above estimate Oct 28, 2026
Latest report · EPS vs estimate
Above estimate Oct 28, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 28, 2026$11.82B$11.78B$1.4700$1.4000
Jul 28, 2026$11.18B$11.02B$1.3600$1.2700
Apr 29, 2026$10.30B$10.23B$1.2400$1.1600
Feb 4, 2026$11.78B$11.41B$0.6800$0.6400
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025£8.55B£2.01B£0.98 (diluted)
Q4 FY2025£8.62B£636M£0.31 (diluted)
Q1 FY2026£7.63B£1.74B£0.85 (diluted)
Q2 FY2026£8.41B£435M£0.21 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for GSK (GSK)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, positive momentum as strengths. The distress and quality screens read Altman Z 1.80 · Piotroski F 8. Trailing ratios: ROE 28.3% · ROA 9.6% · current ratio 0.86.

4 · What to check next?

What should you watch next at GSK (GSK)?

Short answer · as of

The next earnings report is expected on Feb 3, 2027. Current published price targets run low $55.90 · high $60.00 · consensus $57.95 · median $57.95 against a quoted price of $48.58 (as of Nov 18, 2026).

What the records here don't tell us

  • Detailed statement figures are not shown because their conversion to USD has not been verified.
  • No forward revenue or earnings estimate is on file.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does GSK compare with its peers?

Short answer

GSK's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
McKesson Corporation (MCK) Named competitor$1084.43 Nov 18, 2026$125B92 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Named competitor$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
Sanofi (SNY) Named competitor$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Same industry, near in market value$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Same industry, near in market value$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Same industry, near in market value$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
CVS Health Corporation (CVS) Named competitor$81.34 Nov 18, 2026$104B81 5-pillar Nov 18, 2026
GSK (GSK) — this page$48.58$97.4B77
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$55.90 – $60.00
Consensus target
$57.95
Median target
$57.95

Consensus record · Captured .

Measured against a quoted price of $48.58 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GSK in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.11%$26.43MAdded +8.8% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about GSK (GSK)?

Read these with our analysis →

GSK Healthcare Stock: Key Questions Answered

Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.

How do GSK vaccines change the way its business should be read?

GSK earns from prevention as well as treatment, with vaccines addressing shingles, meningitis, respiratory syncytial virus, influenza and polio. Immunization uptake therefore matters alongside demand for HIV, oncology, respiratory, immunology and anti-infective medicines.

Why are CureVac, Wave Life Sciences and Elsie Biotechnologies relevant to GSK?

CureVac supports messenger RNA influenza work, while Wave Life Sciences and Elsie Biotechnologies contribute oligonucleotide platforms. These collaborations extend GSK’s research reach beyond programs developed solely inside the company.

What is the GSK stock price today?

The last price recorded for GSK plc (GSK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GSK price target?

The analyst consensus price target for GSK plc (GSK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 41 figures on this page — 1 from SEC filings and earnings calls, 32 from Financial Modeling Prep (FMP), 4 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • FAQ: How do GSK vaccines change the way its business should be read?: Business description
  • FAQ: Why are CureVac, Wave Life Sciences and Elsie Biotechnologies relevant to GSK?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.